Literature DB >> 22611158

APELIN promotes hematopoiesis from human embryonic stem cells.

Qing C Yu1, Claire E Hirst, Magdaline Costa, Elizabeth S Ng, Jacqueline V Schiesser, Karin Gertow, Edouard G Stanley, Andrew G Elefanty.   

Abstract

Transcriptional profiling of differentiating human embryonic stem cells (hESCs) revealed that MIXL1-positive mesodermal precursors were enriched for transcripts encoding the G-protein-coupled APELIN receptor (APLNR). APLNR-positive cells, identified by binding of the fluoresceinated peptide ligand, APELIN (APLN), or an anti-APLNR mAb, were found in both posterior mesoderm and anterior mesendoderm populations and were enriched in hemangioblast colony-forming cells (Bl-CFC). The addition of APLN peptide to the media enhanced the growth of embryoid bodies (EBs), increased the expression of hematoendothelial genes in differentiating hESCs, and increased the frequency of Bl-CFCs by up to 10-fold. Furthermore, APLN peptide also synergized with VEGF to promote the growth of hESC-derived endothelial cells. These studies identified APLN as a novel growth factor for hESC-derived hematopoietic and endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22611158     DOI: 10.1182/blood-2011-12-396093

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

Review 1.  Generating human hematopoietic stem cells in vitro -exploring endothelial to hematopoietic transition as a portal for stemness acquisition.

Authors:  Igor I Slukvin
Journal:  FEBS Lett       Date:  2016-07-22       Impact factor: 4.124

2.  Productive Infection of Human Embryonic Stem Cell-Derived NKX2.1+ Respiratory Progenitors with Human Rhinovirus.

Authors:  Robert A Jenny; Claire Hirst; Sue Mei Lim; Adam L Goulburn; Suzanne J Micallef; Tanya Labonne; Anthony Kicic; Kak-Ming Ling; Stephen M Stick; Elizabeth S Ng; Alan Trounson; Antonietta Giudice; Andrew G Elefanty; Edouard G Stanley
Journal:  Stem Cells Transl Med       Date:  2015-04-14       Impact factor: 6.940

Review 3.  Hematopoietic specification from human pluripotent stem cells: current advances and challenges toward de novo generation of hematopoietic stem cells.

Authors:  Igor I Slukvin
Journal:  Blood       Date:  2013-10-11       Impact factor: 22.113

Review 4.  The Patentability of Stem Cells in Australia.

Authors:  Jenny Petering; Prue Cowin
Journal:  Cold Spring Harb Perspect Med       Date:  2015-07-01       Impact factor: 6.915

5.  Wnt signaling promotes hindgut fate commitment through regulating multi-lineage genes during hESC differentiation.

Authors:  Xiujuan Zhang; Ying Chen; Ying Ye; Jianfeng Wang; Hong Wang; Guohong Yuan; Zhe Lin; Yihui Wu; Yan Zhang; Xinhua Lin
Journal:  Cell Signal       Date:  2016-09-29       Impact factor: 4.315

Review 6.  Apelinergic System Structure and Function.

Authors:  Kyungsoo Shin; Calem Kenward; Jan K Rainey
Journal:  Compr Physiol       Date:  2017-12-12       Impact factor: 9.090

7.  The migratory pathways of the cells that form the endocardium, dorsal aortae, and head vasculature in the mouse embryo.

Authors:  C Collart; A Ciccarelli; K Ivanovitch; I Rosewell; S Kumar; G Kelly; A Edwards; J C Smith
Journal:  BMC Dev Biol       Date:  2021-03-22       Impact factor: 1.978

8.  WNT3A promotes hematopoietic or mesenchymal differentiation from hESCs depending on the time of exposure.

Authors:  Karin Gertow; Claire E Hirst; Qing C Yu; Elizabeth S Ng; Lloyd A Pereira; Richard P Davis; Edouard G Stanley; Andrew G Elefanty
Journal:  Stem Cell Reports       Date:  2013-06-04       Impact factor: 7.765

Review 9.  Deciphering the hierarchy of angiohematopoietic progenitors from human pluripotent stem cells.

Authors:  Igor I Slukvin
Journal:  Cell Cycle       Date:  2013-02-06       Impact factor: 4.534

10.  Generation of megakaryocytic progenitors from human embryonic stem cells in a feeder- and serum-free medium.

Authors:  Marjorie Pick; Lisa Azzola; Elissa Osborne; Edouard G Stanley; Andrew G Elefanty
Journal:  PLoS One       Date:  2013-02-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.